BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: For all single agent treatment, the average net increase in apoptosis, for primary CML cells without the BIM deletion polymorphism, was 33% and for those with the polymorphism, it was 15% (Figure 5A).